For Industry

PDUFA Meetings

FDA periodically conducts meetings on the Prescription Drug User Fee Act (PDUFA) program. The current legislative authority for PDUFA (PDUFA V), reauthorized in 2012 by the Food and Drug Administration Safety and Innovation Act (FDASIA), will expire in September 2017. The Federal Food, Drug, and Cosmetic Act (FD&C Act) requires that FDA hold public meetings and conduct discussions with both the regulated industry and stakeholder groups in developing recommendations for the next PDUFA program (FY2018-2022).  More information on the upcoming reauthorization effort can be found here:  PDUFA VI

This page contains information for both the public part of the PDUFA reauthorization process and the discussions FDA holds with industry and stakeholders.

PDUFA V Public Meetings

Information about the three major public meetings that were held for PDUFA V

Page Last Updated: 12/14/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English